The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Open accessAbstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of ∼36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune responses are improved by introducing two consecutive proline residues (2P), which are known to retain the full-length S protein in the prefusion conformation.64,65”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both vaccines encode the same full-length, pre-fusion stabilized severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein13,14 and are encapsulated in lipid nanoparticles (LNPs) with identical composition.”
From Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stabilizing coronavirus spike proteins by substituting two prolines at the top of heptad repeat 1 prevents structural rearrangements of the fusion (S2) subunit.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, S-2P conformational stability translates into greater immunogenicity,27-29 based on preservation of neutralization-sensitive epitopes at the apex of the prefusion molecule, as shown for respiratory syncytial virus F glycoprotein,30 and improved protein expression,27 which is particularly advantageous for gene-based antigen delivery.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 46,047
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
RELION: Implementation of a Bayesian approach to cryo-EM structure determination
Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,743
Comparative Protein Structure Modeling Using MODELLER
Webb, B., & Šali, A. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.3 · Cited by 4,404
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
Cited by
Sorted by citations
Items 101–200 of 1,000
Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection
Menachery, V. D., Dinnon, K. H., Yount, B. L., McAnarney, E. T., Gralinski, L. E., Hale, A., Graham, R. L., Scobey, T., Anthony, S. J., Wang, L., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01774-19 · Cited by 205
Self-citationThépaut, M., Luczkowiak, J., Vivès, C., Labiod, N., Bally, I., Lasala, F., Grimoire, Y., Fenel, D., Sattin, S., Thielens, N. M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009576 · Cited by 222
Zhou, P.-P., Yuan, M., Song, G., Beutler, N., Shaabani, N., Huang, D., He, W., Zhu, X., Callaghan, S., Yong, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9215 · Cited by 196
Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 209
Self-citationKremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J. J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., Schindler, C., et al. (2020) · doi:10.1101/2020.11.09.20228551 · Cited by 199
A simple protein-based surrogate neutralization assay for SARS-CoV-2
Abe, K. T., Li, Z., Samson, R., Samavarchi‐Tehrani, P., Valcourt, E. J., Wood, H., Budylowski, P., Dupuis, A. P., Girardin, R. C., Rathod, B., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142362 · Cited by 200
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
Walls, A. C., Sprouse, K. R., Bowen, J. E., Joshi, A., Franko, N., Navarro, M. J., Stewart, C., Cameroni, E., McCallum, M., Goecker, E. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.011 · Cited by 188
Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection
Brouwer, P. J. M., Brinkkemper, M., Maisonnasse, P., Dereuddre‐Bosquet, N., Grobben, M., Claireaux, M. A. F., de Gast, M., Marlin, R., Chesnais, V., Diry, S., et al. (2020) · Cell · doi:10.1016/j.cell.2021.01.035 · Cited by 188
Self-citationSerologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses
Hicks, J., Klumpp-Thomas, C. A., Kalish, H. R., Shunmugavel, A., Mehalko, J. L., Denson, J.-P., Snead, K., Drew, M. R., Corbett, K. S., Graham, B. S., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-00997-6 · Cited by 192
Self-citationStructural basis for broad coronavirus neutralization
Sauer, M. M., Tortorici, M. A., Park, Y., Walls, A. C., Homad, L. J., Acton, O. J., Bowen, J. E., Wang, C., Xiong, X., de van der Schueren, W., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00596-4 · Cited by 175
Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID‐19
Hur, K., Price, C. P. E., Gray, E., Gulati, R. K., Maksimoski, M. T., Racette, S. D., Schneider, A. L., & Khanwalkar, A. R. (2020) · Otolaryngology · doi:10.1177/0194599820929640 · Cited by 187
Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185
“(D) SARS-CoV-2 S2P (left) or SARS-CoV S2P (right) Ab binding titers of RBD-NP-elicited sera in pigtail macaques (magenta) or HexaPro S-elicited sera in rhesus macaques (gray) analyzed by ELISA with an LOD of 2.53 101.”
InfluentialSelf-citationPowell, A. E., Zhang, K., Sanyal, M., Tang, S., Weidenbacher, P. A. B., Li, S., Pham, T. D., Pak, J. E., Chiu, W., & Kim, P. S. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01405 · Cited by 174
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
Joyce, M. G., Chen, W., Sankhala, R. S., Hajduczki, A., Thomas, P. V., Choe, M., Martinez, E. J., Chang, W. C., Peterson, C. E., Morrison, E. B., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110143 · Cited by 180
Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19
Andryukov, B. G. (2020) · AIMS Microbiology · doi:10.3934/microbiol.2020018 · Cited by 185
McCallum, M., Walls, A. C., Bowen, J. E., Corti, D., & Veesler, D. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0483-8 · Cited by 166
Broadly neutralizing antibodies target a haemagglutinin anchor epitope
Guthmiller, J. J., Han, J., Utset, H. A., Li, L., Lan, L. Y.-L., Henry, C., Stamper, C. T., McMahon, M., O’Dell, G., Fernández‐Quintero, M. L., et al. (2021) · Nature · doi:10.1038/s41586-021-04356-8 · Cited by 177
Self-citationWang, L., Shi, W., Chappell, J. D., Joyce, M. G., Zhang, Y., Kanekiyo, M., Becker, M. M., van Doremalen, N., Fischer, R., Wang, N., et al. (2018) · Journal of Virology · doi:10.1128/jvi.02002-17 · Cited by 169
Self-citationKuo, T.-Y., Lin, M., Coffman, R. L., Campbell, J. D., Traquina, P., Lin, Y.-J., Liu, L. T.-C., Cheng, J., Wu, Y.-C., Wu, C.-C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77077-z · Cited by 163
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
Low, J. S., Jerak, J., Tortorici, M. A., McCallum, M., Pinto, D., Cassotta, A., Foglierini, M., Mele, F., Abdelnabi, R., Weynand, B., et al. (2022) · Science · doi:10.1126/science.abq2679 · Cited by 163
Rahman, M. S., Hoque, M. N., Islam, M. R., Akter, S., Alam, A. R.-U., Siddique, M. A., Saha, O., Rahaman, M. M., Sultana, M., Crandall, K. A., et al. (2020) · PeerJ · doi:10.7717/peerj.9572 · Cited by 166
Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines · doi:10.1038/s41541-021-00311-w · Cited by 165
Stabilizing the closed SARS-CoV-2 spike trimer
Juraszek, J., Rutten, L., Blokland, S., Bouchier, P., Voorzaat, R., Ritschel, T., Bakkers, M. J. G., Renault, L. L. R., & Langedijk, J. P. M. (2021) · Nature Communications · doi:10.1038/s41467-020-20321-x · Cited by 157
Close relatives of MERS-CoV in bats use ACE2 as their functional receptors
Xiong, Q., Cao, L., Ma, C., Tortorici, M. A., Liu, C., Si, J., Liu, P., Gu, M., Walls, A. C., Wang, C., et al. (2022) · Nature · doi:10.1038/s41586-022-05513-3 · Cited by 160
Xiong, X., Tortorici, M. A., Snijder, J., Yoshioka, C., Walls, A. C., Li, W., McGuire, A. T., Rey, F. A., Bosch, B., & Veesler, D. (2017) · Journal of Virology · doi:10.1128/jvi.01628-17 · Cited by 156
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
Watanabe, Y., Mendonça, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F. R., Davies, H. D., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00080 · Cited by 155
Shang, J., Zheng, Y., Yang, Y., Liu, C., Geng, Q., Luo, C., Zhang, W., & Li, F. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007009 · Cited by 158
COVID-19 vaccine: where are we now and where should we go?
Soleimanpour, S., & Yaghoubi, A. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1875824 · Cited by 155
Zhou, H., Chen, Y., Zhang, S., Niu, P., Qin, K., Jia, W., Huang, B., Zhang, S., Lan, J., Zhang, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10897-4 · Cited by 148
Structure and Immune Recognition of the HIV Glycan Shield
Crispin, M., Ward, A. B., & Wilson, I. A. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-060414-034156 · Cited by 140
Self-citationAntigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
Rijkers, G. T., Weterings, N., Obregón‐Henao, A., Dutt, T., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. I. (2021) · Vaccines · doi:10.3390/vaccines9080848 · Cited by 139
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures
Eroshenko, N., Gill, T., Keaveney, M. K., Church, G. M., Trevejo, J., & Rajaniemi, H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0577-1 · Cited by 122
Zhang, B., Chao, C. W., Tsybovsky, Y., Abiona, O. M., Hutchinson, G. B., Moliva, J. I., Olia, A. S., Pegu, A., Phung, E., Stewart-Jones, G. B. E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74949-2 · Cited by 127
Self-citationPEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition
Lin, F., Zhang, H., Li, L., Yang, Y., Zou, X., Chen, J., & Tang, X. (2022) · Viruses · doi:10.3390/v14081744 · Cited by 132
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2022) · Nature · doi:10.1038/s41586-021-04231-6 · Cited by 127
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126
Prospects for a MERS-CoV spike vaccine
Zhou, Y., Jiang, S., & Du, L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506702 · Cited by 126
Hunt, A. C., Case, J. B., Park, Y., Cao, L., Wu, K., Walls, A. C., Liu, Z., Bowen, J. E., Yeh, A. H.-W., Saini, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1252 · Cited by 121
Lambert, P.-H., Ambrosino, D. M., Andersen, S. R., Baric, R. S., Black, S. B., Chen, R. T., Dekker, C. L., Didierlaurent, A. M., Graham, B. S., Martin, S. D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.064 · Cited by 119
Self-citationMolecular Investigation of SARS–CoV-2 Proteins and Their Interactions with Antiviral Drugs
Calligari, P. A., Bobone, S., Ricci, G., & Bocedi, A. (2020) · Viruses · doi:10.3390/v12040445 · Cited by 123
Teng, S., Sobitan, A., Rhoades, R. E., Liu, D., & Tang, Q. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa233 · Cited by 117
He, L., Lin, X., Wang, Y., Abraham, C., Sou, C., Ngo, T., Zhang, Y., Wilson, I. A., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abf1591 · Cited by 121
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
Goepfert, P., Fu, B., Chabanon, A.-L., Bonaparte, M. I., Davis, M., Essink, B. J., Frank, I., Haney, O., Janosczyk, H., Keefer, M. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00147-x · Cited by 114
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
Zhou, Y., Yang, Y., Huang, J., Jiang, S., & Du, L. (2019) · Viruses · doi:10.3390/v11010060 · Cited by 120
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 115
Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
Granados-Riveron, J. T., & Aquino‐Jarquín, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111953 · Cited by 115
Caniels, T. G., Bontjer, I., van der Straten, K., Poniman, M., Burger, J. A., Appelman, B., Lavell, A. H. A., Oomen, M., Godeke, G.-J., Valle, C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5365 · Cited by 107
Kaur, N., Singh, R., Dar, Z., Bijarnia, R. K., Dhingra, N., & Kaur, T. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104490 · Cited by 115
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
Edwards, A. M., Baric, R. S., Saphire, E. O., & Ulmer, J. B. (2022) · Science · doi:10.1126/science.abn1900 · Cited by 109
The Challenges of Vaccine Development against a New Virus during a Pandemic
Diamond, M., & Pierson, T. C. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.021 · Cited by 108
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Chiu, H.-P., Stevens, C. S., Vilardo, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24909-9 · Cited by 141
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Stuart, A. B., Edara, V. V., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109353 · Cited by 108
Self-citationRational Vaccine Design in the Time of COVID-19
Burton, D., & Walker, L. (2020) · Cell Host and Microbe · doi:10.1016/j.chom.2020.04.022 · Cited by 112
Kacherovsky, N. A., Yang, L. F., Dang, H. V., Cheng, E. L., Cardle, I. I., Walls, A. C., McCallum, M., Sellers, D. L., DiMaio, F., Salipante, S. J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202107730 · Cited by 107
Prospects for mucosal vaccine: shutting the door on SARS-CoV-2
Mudgal, R. K., Nehul, S., & Tomar, S. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1805992 · Cited by 103
Wrapp, D., & McLellan, J. S. (2019) · Journal of Virology · doi:10.1128/jvi.00923-19 · Cited by 106
Self-citationDevelopment of vaccines and antivirals for combating viral pandemics
Pardi, N., & Weissman, D. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00658-w · Cited by 108
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Dagotto, G., Yu, J., & Barouch, D. H. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.08.002 · Cited by 103
Virus vaccines: proteins prefer prolines
Sanders, R. W., & Moore, J. P. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.002 · Cited by 97
Rutten, L., Lai, Y., Blokland, S., Truan, D., Bisschop, I. J. M., Strokappe, N. M., Koornneef, A., van Manen, D., Chuang, G., Farney, S. K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.061 · Cited by 101
Tse, L. V., Meganck, R. M., Graham, R. L., & Baric, R. S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00658 · Cited by 101
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
Zhang, C., Wang, Y., Zhu, Y., Liu, C., Gu, C., Xu, S., Wang, Y., Zhou, Y., Wang, Y., Han, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20465-w · Cited by 101
Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production
Zhao, X., Chen, H., & Wang, H. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.629873 · Cited by 103
Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike
Stalls, V., Lindenberger, J. J., Gobeil, S., Henderson, R. C., Parks, R., Barr, M., Deyton, M., Martin, M., Janowska, K., Huang, X., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111009 · Cited by 101
Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K. E., Wieland‐Alter, W., Connor, R. I., Wright, P. F., et al. (2021) · mBio · doi:10.1128/mbio.00765-21 · Cited by 99
The advent of clinical self-amplifying RNA vaccines
Casmil, I. C., Jin, J., Won, E.-J., Huang, C., Liao, S., Cha‐Molstad, H., & Blakney, A. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.060 · Cited by 111
Stabilized coronavirus spike stem elicits a broadly protective antibody
Hsieh, C., Werner, A. P., Leist, S. R., Stevens, L. J., Falconer, E., Goldsmith, J. A., Chou, C., Abiona, O. M., West, A., Westendorf, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109929 · Cited by 93
Self-citationProtection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
Corbett, K. S., Gagné, M., Wagner, D. A., Connell, S. O., Narpala, S., Flebbe, D. R., Andrew, S. F., Davis, R. L., Flynn, B. J., Johnston, T. S., et al. (2021) · Science · doi:10.1126/science.abl8912 · Cited by 98
Self-citationAdvances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 99
Garg, I., Shekhar, R., Sheikh, A. B., & Pal, S. (2021) · Infectious Disease Reports · doi:10.3390/idr13030064 · Cited by 104
Song, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2020) · doi:10.1101/2020.09.22.308965 · Cited by 285
Self-citationSkariyachan, S., Challapilli, S. B., Packirisamy, S., Kumargowda, S. T., & Sridhar, V. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00569 · Cited by 99
DiPiazza, A. T., Leist, S. R., Abiona, O. M., Moliva, J. I., Werner, A. P., Minai, M., Nagata, B. M., Bock, K. W., Phung, E., Schäfer, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.018 · Cited by 92
Self-citationStructure and immune recognition of the porcine epidemic diarrhea virus spike protein
Kirchdoerfer, R. N., Bhandari, M. A., Martini, O., Sewall, L. M., Bangaru, S., Yoon, K. J., & Ward, A. B. (2020) · Structure · doi:10.1016/j.str.2020.12.003 · Cited by 98
Self-citationVaccinology in the post−COVID-19 era
Rappuoli, R., Gregorio, E. D., Giudice, G. D., Phogat, S. K., Pecetta, S., Pizza, M., & Hanon, E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020368118 · Cited by 95
Evolutionary Landscapes of Host-Virus Arms Races
Tenthorey, J. L., Emerman, M., & Malik, H. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-072621-084422 · Cited by 105
Architecture and antigenicity of the Nipah virus attachment glycoprotein
Wang, Z., Amaya, M., Addetia, A., Dang, H. V., Reggiano, G., Yan, L., Hickey, A. C., DiMaio, F., Broder, C. C., & Veesler, D. (2022) · Science · doi:10.1126/science.abm5561 · Cited by 94
Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y., Eguia, R. T., Miranda, M. C., Kepl, E., Dosey, A. M., Stevens‐Ayers, T., Boeckh, M. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.019 · Cited by 89
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., West, A. P., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.024 · Cited by 104
The Hantavirus Surface Glycoprotein Lattice and Its Fusion Control Mechanism
Serris, A., Stass, R., Bignon, E. A., Muena, N. A., Manuguerra, J., Jangra, R. K., Li, S., Chandran, K., Tischler, N. D., Huiskonen, J. T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.023 · Cited by 96
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
Díaz-Salinas, M. A., Li, Q., Ejemel, M., Yurkovetskiy, L., Luban, J., Shen, K., Wang, Y., & Munro, J. B. (2022) · eLife · doi:10.7554/elife.75433 · Cited by 81
Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site
Kalathiya, U., Padariya, M., Mayordomo, M. Y., Lisowska, M. M., Nicholson, J., Singh, A. J., Bagiński, M., Fåhræus, R., Carragher, N. O., Ball, K. L., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051473 · Cited by 93
Peng, C., Zhu, Z., Shi, Y., Wang, X., Mu, K., Yang, Y., Zhang, X., Xu, Z., & Zhu, W. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02958 · Cited by 90
Harbison, A. M., Fogarty, C. A., Phung, T. K., Satheesan, A., Schulz, B. L., & Fadda, E. (2021) · Chemical Science · doi:10.1039/d1sc04832e · Cited by 86
Global site-specific analysis of glycoprotein N-glycan processing
Cao, L., Diedrich, J. K., Ma, Y., Wang, N., Pauthner, M. G., Park, S.-K. R., Delahunty, C. M., McLellan, J. S., Burton, D. R., Yates, J. R., et al. (2018) · Nature Protocols · doi:10.1038/nprot.2018.024 · Cited by 91
Self-citationLoomis, R. J., Stewart-Jones, G. B. E., Tsybovsky, Y., Caringal, R. T., Morabito, K. M., McLellan, J. S., Chamberlain, A. L., Nugent, S. T., Hutchinson, G. B., Kueltzo, L. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00842 · Cited by 93
Self-citationSARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 90
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92
Silva, R. P., Huang, Y., Nguyen, A. W., Hsieh, C., Olaluwoye, O. S., Kaoud, T. S., Wilen, R. E., Qerqez, A. N., Park, J., Khalil, A. M., et al. (2023) · eLife · doi:10.7554/elife.83710 · Cited by 86
Self-citationA self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89
Routhu, N. K., Cheedarla, N., Gangadhara, S., Bollimpelli, V. S., Boddapati, A. K., Shiferaw, A., Rahman, S. A., Sahoo, A., Edara, V. V., Lai, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.001 · Cited by 85
Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype
Pascolo, S. (2021) · Viruses · doi:10.3390/v13020270 · Cited by 87
Huang, Q., Zeng, J., & Yan, J. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.02.006 · Cited by 91
Structural Definition of a Neutralization-sensitive Epitope on the MERS-CoV S1-NTD
Wang, N., Rosen, O., Wang, L., Turner, H. L., Stevens, L. J., Corbett, K. S., Bowman, C. A., Pallesen, J., Shi, W., Zhang, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.052 · Cited by 86
Self-citationPoint-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives
Hussein, H. A., Hassan, R. Y. A., Chino, M., & Febbraio, F. (2020) · Sensors · doi:10.3390/s20154289 · Cited by 87
Wrobel, A. G., Benton, D. J., Xu, P., Calder, L. J., Borg, A., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2021) · Nature Communications · doi:10.1038/s41467-021-21006-9 · Cited by 85
Antibodies and vaccines against Middle East respiratory syndrome coronavirus
Xu, J., Jia, W., Wang, P., Zhang, S., Shi, X., Wang, X., & Zhang, L. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1624482 · Cited by 84
The prefusion structure of herpes simplex virus glycoprotein B
Vollmer, B., Pražák, V., Vasishtan, D., Jefferys, E. E., Durán, A. H., Vallbracht, M., Klupp, B. G., Mettenleiter, T. C., Backović, M., Rey, F. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc1726 · Cited by 87
Metadata
- Authors
- Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., & McLellan, J. S.
- Affiliations
- Scripps Research Institute (US)
- Dartmouth College (US)
- National Institute of Allergy and Infectious Diseases (US)
- Vanderbilt University Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Pallesen, Jesper
- Wang, Nianshuang
- Corbett, Kizzmekia S.
- Ward, Andrew B.
- McLellan, Jason S.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-08-14
- Volume
- 114
- Issue
- 35
- Pages
- E7348-E7357
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5584442
- OpenAlex
- W2750464792
- Cited by
- 1,073
- References
- 89
- Citations by year
- 2026: 48 · 2025: 75 · 2024: 98 · 2023: 127 · 2022: 174 · 2021: 275 · 2020: 220 · 2019: 31 · 2018: 17 · 2017: 6
- FWCI
- 57.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI127521)
- HHS | NIH | National Institute of General Medical Sciences (P20GM113132)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI005125)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- MERS-CoV, spike protein, structure-based vaccine design, neutralizing antibodies, receptor binding domain, receptor recognition, membrane fusion mechanism, coronavirus vaccines
- MeSH terms
- Animals, Antibodies, Viral, Coronaviridae, Humans, Immunoglobulin G, Mice, Inbred BALB C, Protein Binding, Protein Conformation, Receptors, Virus, Structure-Activity Relationship, Vaccination, Viral Vaccines, Coronavirus Infections, Crystallography, X-Ray, Immunity, Humoral, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
